These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 32865785)

  • 1. Degradation of Toxic RNA in Myotonic Dystrophy Using Gapmer Antisense Oligonucleotides.
    Nguyen Q; Yokota T
    Methods Mol Biol; 2020; 2176():99-109. PubMed ID: 32865785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short antisense-locked nucleic acids (all-LNAs) correct alternative splicing abnormalities in myotonic dystrophy.
    Wojtkowiak-Szlachcic A; Taylor K; Stepniak-Konieczna E; Sznajder LJ; Mykowska A; Sroka J; Thornton CA; Sobczak K
    Nucleic Acids Res; 2015 Mar; 43(6):3318-31. PubMed ID: 25753670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RNase H-mediated degradation of toxic RNA in myotonic dystrophy type 1.
    Lee JE; Bennett CF; Cooper TA
    Proc Natl Acad Sci U S A; 2012 Mar; 109(11):4221-6. PubMed ID: 22371589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AON-induced splice-switching and DMPK pre-mRNA degradation as potential therapeutic approaches for Myotonic Dystrophy type 1.
    Stepniak-Konieczna E; Konieczny P; Cywoniuk P; Dluzewska J; Sobczak K
    Nucleic Acids Res; 2020 Mar; 48(5):2531-2543. PubMed ID: 31965181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BNA
    Manning KS; Rao AN; Castro M; Cooper TA
    ACS Chem Biol; 2017 Oct; 12(10):2503-2509. PubMed ID: 28853853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic therapy in an RNA toxicity mouse model with an antisense oligonucleotide therapy targeting a non-CUG sequence within the DMPK 3'UTR RNA.
    Yadava RS; Yu Q; Mandal M; Rigo F; Bennett CF; Mahadevan MS
    Hum Mol Genet; 2020 Jun; 29(9):1440-1453. PubMed ID: 32242217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antisense oligonucleotides: rising stars in eliminating RNA toxicity in myotonic dystrophy.
    Gao Z; Cooper TA
    Hum Gene Ther; 2013 May; 24(5):499-507. PubMed ID: 23252746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy.
    Mulders SA; van den Broek WJ; Wheeler TM; Croes HJ; van Kuik-Romeijn P; de Kimpe SJ; Furling D; Platenburg GJ; Gourdon G; Thornton CA; Wieringa B; Wansink DG
    Proc Natl Acad Sci U S A; 2009 Aug; 106(33):13915-20. PubMed ID: 19667189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RNA-mediated therapies in myotonic dystrophy.
    Overby SJ; Cerro-Herreros E; Llamusi B; Artero R
    Drug Discov Today; 2018 Dec; 23(12):2013-2022. PubMed ID: 30086404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced Delivery of Ligand-Conjugated Antisense Oligonucleotides (C16-HA-ASO) Targeting Dystrophia Myotonica Protein Kinase Transcripts for the Treatment of Myotonic Dystrophy Type 1.
    Ait Benichou S; Jauvin D; De Serres-Bérard T; Bennett F; Rigo F; Gourdon G; Boutjdir M; Chahine M; Puymirat J
    Hum Gene Ther; 2022 Aug; 33(15-16):810-820. PubMed ID: 35794764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myotonic dystrophy: emerging mechanisms for DM1 and DM2.
    Cho DH; Tapscott SJ
    Biochim Biophys Acta; 2007 Feb; 1772(2):195-204. PubMed ID: 16876389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting nuclear RNA for in vivo correction of myotonic dystrophy.
    Wheeler TM; Leger AJ; Pandey SK; MacLeod AR; Nakamori M; Cheng SH; Wentworth BM; Bennett CF; Thornton CA
    Nature; 2012 Aug; 488(7409):111-5. PubMed ID: 22859208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic delivery of a Peptide-linked morpholino oligonucleotide neutralizes mutant RNA toxicity in a mouse model of myotonic dystrophy.
    Leger AJ; Mosquea LM; Clayton NP; Wu IH; Weeden T; Nelson CA; Phillips L; Roberts E; Piepenhagen PA; Cheng SH; Wentworth BM
    Nucleic Acid Ther; 2013 Apr; 23(2):109-17. PubMed ID: 23308382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic Approaches for Dominant Muscle Diseases: Highlight on Myotonic Dystrophy.
    Klein AF; Dastidar S; Furling D; Chuah MK
    Curr Gene Ther; 2015; 15(4):329-37. PubMed ID: 26122101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. (CCUG)
    Yenigun VB; Sirito M; Amcheslavky A; Czernuszewicz T; Colonques-Bellmunt J; García-Alcover I; Wojciechowska M; Bolduc C; Chen Z; López Castel A; Krahe R; Bergmann A
    Dis Model Mech; 2017 Aug; 10(8):993-1003. PubMed ID: 28623239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Muscleblind localizes to nuclear foci of aberrant RNA in myotonic dystrophy types 1 and 2.
    Mankodi A; Urbinati CR; Yuan QP; Moxley RT; Sansone V; Krym M; Henderson D; Schalling M; Swanson MS; Thornton CA
    Hum Mol Genet; 2001 Sep; 10(19):2165-70. PubMed ID: 11590133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and characterization of modified antisense oligonucleotides targeting DMPK in mice and nonhuman primates for the treatment of myotonic dystrophy type 1.
    Pandey SK; Wheeler TM; Justice SL; Kim A; Younis HS; Gattis D; Jauvin D; Puymirat J; Swayze EE; Freier SM; Bennett CF; Thornton CA; MacLeod AR
    J Pharmacol Exp Ther; 2015 Nov; 355(2):329-40. PubMed ID: 26330536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent Progress and Challenges in the Development of Antisense Therapies for Myotonic Dystrophy Type 1.
    De Serres-Bérard T; Ait Benichou S; Jauvin D; Boutjdir M; Puymirat J; Chahine M
    Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular therapy in myotonic dystrophy: focus on RNA gain-of-function.
    Mulders SA; van Engelen BG; Wieringa B; Wansink DG
    Hum Mol Genet; 2010 Apr; 19(R1):R90-7. PubMed ID: 20406734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antisense oligonucleotides as a potential treatment for brain deficits observed in myotonic dystrophy type 1.
    Ait Benichou S; Jauvin D; De Serres-Bérard T; Pierre M; Ling KK; Bennett CF; Rigo F; Gourdon G; Chahine M; Puymirat J
    Gene Ther; 2022 Dec; 29(12):698-709. PubMed ID: 35075265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.